Why Herbalife Earnings Didn’t Impress Investors

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why Herbalife Earnings Didn’t Impress Investors

© courtesy of Herbalife Ltd.

[cnxvideo id=”625456″ placement=”ros”]Herbalife Ltd. (NYSE: HLF) reported fourth-quarter and full-year 2016 results after the markets closed Thursday. The nutrition and weight loss company posted adjusted diluted earnings per share (EPS) of $1.00 on revenues of $1.05 billion. In the same period a year ago, Herbalife reported EPS of $1.17 on revenues of $1.1 billion. The consensus estimates called for EPS of $0.97 and $1.05 billion in revenue.

For the full year Herbalife reported adjusted EPS of $4.85 and revenues of $4.49 billion compared with EPS of $4.95 and revenues of $4.47 billion in 2015. Analysts were looking for EPS of $4.84 and revenues of $4.49 billion. Foreign currency exchange rates cost the company $0.95 per share for the full year and $0.11 per share in the fourth quarter.

In a separate press release this afternoon, the company announced that it has reached an agreement in principle to form a joint venture with China’s Tasly Holding Group, a traditional Chinese medicine provider.

[nativounit]

CEO Michael Johnson said:

2016 was a dynamic and record-breaking year. Our members continue to successfully build customer-focused businesses, which is evident in our record volume and retention metrics. In addition, our new share buyback authorization is a further testament of our commitment to enhance shareholder value.

Excluding the impact of share buybacks, Herbalife expects first-quarter currency-adjusted EPS in a range of $0.85 to $1.05 and full-year EPS of $4.20 to $4.60. First-quarter sales are forecast down 5% to 9% with full-year sales forecast to rise 2% to 5%. Adjusted for currency effects, Herbalife expects first-quarter sales to decline by 3.2% to 7.2% and full-year sales to drop by 3.6% to 6.6%.

Analysts had forecast first-quarter adjusted EPS at $1.29 on sales of $1.12 billion, essentially flat with the year-ago first quarter. Full-year EPS is forecast at $5.00 and sales are tabbed at $4.55 billion.

The company’s weakish outlook will weigh on the shares more than the slight earnings beat. Investors like to hear better news than declining sales and profits well below consensus estimates.

Herbalife shares closed at $59.40 Thursday in a 52-week trading range of $44.36 to $72.22. Shares are down nearly 2% in after-hours trading at $58.25. The consensus 12-month price target was $72.50 before this afternoon’s report.

[wallst_email_signup]

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618